New insights into the mechanisms of childhood food allergies
Open Access
- 31 March 2025
- journal article
- review article
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 36 (4) , e70069
Abstract
IgE‐mediated food allergies are common and can be life‐threatening, especially for children. With increasingly rapid advances in immunological technologies, including the ability to profile highly complex immune features from small sample volumes, our understanding of the immune mechanisms that underpin the development of food allergies continues to grow. This also extends to the immune mechanisms associated with the outcomes of oral immunotherapy (OIT). This review focuses on studies within the past 5 years related to immune signatures associated with food allergy in childhood, immune responses that determine reaction severities to offending allergens, immune alterations that occur during OIT in children, and immune effects of adjunct therapies including omalizumab, dupilumab, and abrocitinib. We conclude by providing a perspective on current evidence and directions for future research that will enable new prediction and screening tools and facilitate the development of effective curative strategies. imageKeywords
This publication has 36 references indexed in Scilit:
- Expression and activation of the steroidogenic enzyme CYP11A1 is associated with IL-13 production in T cells from peanut allergic childrenPLOS ONE, 2020
- Dual transcriptomic and epigenomic study of reaction severity in peanut-allergic childrenJournal of Allergy and Clinical Immunology, 2020
- Mass cytometry reveals cellular fingerprint associated with IgE+ peanut tolerance and allergy in early lifeNature Communications, 2020
- The utility of TNF-α, IL-6 and IL-10 in the diagnosis and/or follow-up food allergyAllergologia et Immunopathologia, 2020
- Expansion of the CD4+ effector T-cell repertoire characterizes peanut-allergic patients with heightened clinical sensitivityJournal of Allergy and Clinical Immunology, 2020
- T-cell phenotypes are associated with serum IgE levels in Amish and Hutterite childrenJournal of Allergy and Clinical Immunology, 2019
- Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescentsClinical & Experimental Allergy, 2019
- Long-Term Outcome of Peanut Oral Immunotherapy Facilitated Initially by OmalizumabThe Journal of Allergy and Clinical Immunology: In Practice, 2019
- A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic IndividualseClinicalMedicine, 2019
- High‐ and low‐dose oral immunotherapy similarly suppress pro‐allergic cytokines and basophil activation in young childrenClinical & Experimental Allergy, 2018